


ATMPs being delivered in the UK



KEY:	Trade Name	Indication	Source	Nonproprietary name
●	Yescarta	1. Primary mediastinal large B-cell lymphoma 2. Relapsed or refractory diffuse large B-cell lymphoma	https://bit.ly/35k4XPR	Axicabtagene Ciloleucel
●	Kymriah	1. relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years 2. relapsed or refractory diffuse large B-cell lymphoma in adults after 2 or more systemic therapies	https://bit.ly/38aWXlr	Tisagenlecleucel
●	Zolgensma	Spinal Muscular Atrophy	https://bit.ly/3qKA3Yv	Onasemnogene abeparvovec
●	Tecartus	Mantle Cell Lymphoma	https://bit.ly/3qJiUhG	Brexucabtagene autoleucel
●	Imlygic	Melanoma	https://bit.ly/35oIFoE	Talimogene laherparepvec
●	Holoclax	Limbal stem cell deficiency after eye burns	https://bit.ly/3tQfVWE	ex vivo expanded autologous human corneal epithelial cells containing stem cells
●	Luxturna	Hereditary retinal dystrophy with mutations of the RPE65 gene	https://bit.ly/3JLs9pc	Voretigene neparvovec
●	Spherox	Symptomatic articular cartilage defects of the knee	https://bit.ly/36yENTw	Autologous chondrocyte implantation with chondrosphere
●	Libmeldy	Metachromatic leukodystrophy (MLD)	https://bit.ly/3Nt6Jzx	Atidarsagene autotemcel

Calendar of Planned AT Services

Name	Approximate Launch Date	Indication	NICE ID	
Tecartus	August 2022	Additional Indications	1494	Blood Cancer
Ciltacabtagene autoleucel	Unknown	Relapsed or refractory multiple myeloma	3816	Blood Cancer
Ciltacabtagene autoleucel	2023	Additional Indications	4012	Blood Cancer
Axicabtagene ciloleuce (Yescarta)	November 2022	Additional Indications	1684, 1685	Blood Cancer
Lisocabtagene maraleucel	2023	High-grade NHL	3887, 3869	Blood Cancer
Tisagenlecleucel (Kymriah)	2022	Additional Indications	3940	Blood Cancer
Idecabtagene vicleucel (Abecma)	2022	Multiple myeloma (4th line)	1442	Blood Cancer
Etranacogene dezaparovec	Late 2023	Haemophilia B	3812	Blood Disorders
Eladocogene exuparovec (Upstaza)	Late 2022	Aromatic L-amino acid decarboxylase deficiency	3791	Neurometabolic disorder
Lenadogene nolparovec (Lumevoq)	2023	Vision loss due to Leber Hereditary Optic Neuropathy	1410	Ophthalmology
Tabelecleucel / tab-cel	Late 2023	Post-transplant lymphoproliferative disorder	1203	Cancers

This information is accurate as of February 2022, it is subject to frequent changes.